GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on a single drug for the treatment of breast cancer. Its stock price reflects sales of this drug and efforts to expand its use, as well as the risks associated with reliance on a single product.
Share prices of companies in the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of breast cancer. We've categorized it under "Breast Cancer," and the chart below shows how investors value companies in this specific and important area of oncology.
Broad Market Index - GURU.Markets
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of breast cancer. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PBYI - Daily change in the company's share price Puma Biotechnology
Shares of Puma Biotechnology, an oncology company, are exhibiting the extreme volatility typical of biotech. change_co tracks reactions to sales data for its drug and new research. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Breast cancer
Puma Biotechnology, Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparing it to PBYI, whose success depends on a single drug, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Puma is a biopharmaceutical company specializing in breast cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Puma shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Puma Biotechnology
For Puma Biotechnology, year-over-year performance tells the story of the life cycle of its sole breast cancer treatment, Nerlynx. Its market capitalization over 12 months reflects the drug's sales volume and the results of studies on its use in other cancer types, which are key to the company's future.
Annual dynamics of market capitalization of the market segment - Breast cancer
Puma Biotechnology, Inc. is a biopharmaceutical company focused on cancer treatment. Its success is heavily dependent on its only commercial drug for breast cancer. The chart below shows how its focused strategy and efforts to expand the reach of its drug are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Puma Biotechnology is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Puma Biotechnology
Puma Biotechnology's performance hinges on its single product. The monthly fluctuations on the chart reflect sales data for its breast cancer treatment, Nerlynx, as well as news about clinical trials aimed at expanding its use.
Monthly dynamics of market capitalization of the market segment - Breast cancer
Puma Biotechnology specializes in breast cancer treatments. This oncology segment is one of the most researched and competitive. The chart below shows how investor sentiment toward biotech companies in this field has fluctuated, often in response to clinical trial data and regulatory approvals.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Puma Biotechnology is a biopharmaceutical company with a single key drug for the treatment of breast cancer. Its stock performance is entirely dependent on the sales of this drug and the results of its clinical trials. It's a focused company, where the success of a single product is crucial.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Puma Biotechnology
Shares of Puma Biotechnology, which focuses on breast cancer treatment, are extremely news-sensitive. Weekly price movements depend on sales data for its sole drug, new trial results, and competitors' actions. The chart below shows the high volatility associated with the commercial success of a single product.
Weekly dynamics of market capitalization of the market segment - Breast cancer
How typical are Puma Biotechnology's dynamics for the pharmaceutical sector? This chart compares the weekly stock price movements of a company with a single breast cancer drug to the industry average. This helps us understand whether its reaction to sales news is more pronounced than that of large, diversified pharmaceutical companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Puma Biotechnology specializes in a breast cancer treatment. This chart compares its weekly performance to the market. It helps us understand how its narrow focus and reliance on the success of a single product make its shares volatile and uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
PBYI - Market capitalization of the company Puma Biotechnology
Puma Biotechnology's market capitalization is the story of a single drug, Nerlynx, for breast cancer. The company's valuation depends almost entirely on the drug's sales volume and its efforts to expand its use. The chart clearly illustrates the risks of a biotech company dependent on a single product.
PBYI - Share of the company's market capitalization Puma Biotechnology within the market segment - Breast cancer
Puma Biotechnology, Inc. holds its market share through its ownership of a drug for the treatment of a specific type of breast cancer. Its market capitalization reflects both the commercial status of this product and the company's efforts to expand its use.
Market capitalization of the market segment - Breast cancer
Here's a chart of the total market capitalization of biotech companies focused on breast cancer treatment. Puma Biotechnology is a prominent player in this field. The chart's performance is closely tied to the commercial success and life cycle of its key drug, Nerlynx.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market value of breast cancer treatment. Puma Biotechnology's market cap is based on the valuation of its drug, which prevents recurrence after primary treatment. The graph shows how a highly specialized drug could capture a critical niche and share of the global oncology market.
Book value capitalization of the company, segment and market as a whole
PBYI - Book value capitalization of the company Puma Biotechnology
Puma Biotechnology's book value represents its intellectual capital. The chart below reflects the valuation of its rights to NERLYNX®, a breast cancer drug. The dynamics show how the company is monetizing its core asset and investing in expanding its use.
PBYI - Share of the company's book capitalization Puma Biotechnology within the market segment - Breast cancer
Puma Biotechnology's core assets include R&D infrastructure and commercial capacity to promote its breast cancer drug. The chart shows the company's share of this highly specialized pharmaceutical infrastructure, focused on solving a specific oncological problem.
Market segment balance sheet capitalization - Breast cancer
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Puma Biotechnology, with its focus on a single oncology drug, appears "light." The company doesn't strive to build gigantic factories; its model is based on the development and commercialization of a specific product.
Book value of all companies included in the broad market index - GURU.Markets
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its primary asset is an approved breast cancer drug. The company's balance sheet is the value of this drug, which has a real impact on the lives of thousands of patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Puma Biotechnology
Puma Biotechnology's balance sheet consists of its cash and the rights to its cancer drug. A market valuation below its book value reflects disappointment in the drug's sales. The MvsBCap_Co < 1 chart tells the story of how high hopes for the drug were dashed in the real world.
Market to book capitalization ratio in a market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company whose main product is a breast cancer treatment. The chart shows how the market perceives the commercial success of this drug and its potential for use in other cancer types. This assessment is heavily dependent on sales data.
Market to book capitalization ratio for the market as a whole
Puma Biotechnology is a biopharmaceutical company focused on developing cancer treatments. Its lead product is Nerlynx, used to treat breast cancer. This chart helps assess how the market perceives biotech companies that already have an approved product on the market but are continuing research.
Debts of the company, segment and market as a whole
PBYI - Company debts Puma Biotechnology
For Puma Biotechnology, a company focused on a breast cancer drug, debt is a tool for marketing and further research. This chart shows how the company finances its commercial activities and clinical trials to expand the indications for its drug. Debt here supports the product's life cycle.
Market segment debts - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its lead product is designed to treat a specific type of breast cancer. This chart shows how the company, with one commercial product, manages its finances, balancing marketing of that drug with investments in further research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. This chart shows its capital structure. For a company whose commercial success depends largely on a single key drug, debt management is critical. Any sales or competitive issues could seriously complicate debt servicing.
Market segment debt to market segment book capitalization - Breast cancer
Puma Biotechnology focuses on breast cancer treatments, a highly competitive area of oncology with high research and marketing costs. The chart shows how the company's debt burden compares to the overall market capitalization and financial risks of the entire oncology sector.
Debt to book value of all companies in the market
Puma Biotechnology (PBYI) is a biopharmaceutical company whose primary product is designed to treat breast cancer. With a commercial product, the company is transitioning from an R&D model to an operating model. This chart shows the overall debt burden of the economy. It allows for a comparison of how PBYI manages its debt now that it has a stable source of income.
P/E of the company, segment and market as a whole
P/E - Puma Biotechnology
This chart shows the valuation of Puma Biotechnology, a company whose main product is a breast cancer treatment. The price-to-earnings ratio is entirely dependent on the sales volume of this single drug. A low value may reflect concerns about the drug's side effects or competition, limiting its market potential.
P/E of the market segment - Breast cancer
This chart shows the average P/E ratio for biopharmaceutical companies. For Puma Biotechnology, with its single commercial product, this is an important benchmark. Comparing its P/E to the industry average helps understand how investors assess the risks associated with reliance on a single drug and its future commercial potential.
P/E of the market as a whole
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its lead product is designed to treat breast cancer. The company's success depends on sales of this drug and the results of new studies. This chart helps assess how the market views biotech companies with a single key product.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its lead product, Nerlynx, is designed to treat a specific type of breast cancer. This graph reflects the expected commercial success of this single drug. The valuation is heavily dependent on its sales volume and the results of studies on its use in other cancer types.
%20P%2FE%20Puma%20Biotechnology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Puma-Biotechnology&v=1772513459770 "Chart of the company's future (projected) P/E Puma Biotechnology")
Future (projected) P/E of the market segment - Breast cancer
Puma Biotechnology specializes in cancer treatments, most notably Nerlynx for breast cancer. This chart compares the company's future profitability expectations with the pharmaceutical industry average. It reflects the market's confidence in the commercial potential of their lead drug and the products they are developing.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772513459771 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. Its primary product is Nerlynx. The company's success depends on sales of this drug and the results of new studies. This market expectations chart influences Puma through the overall assessment of the biotech sector and investor sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513459773 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its only approved drug, Nerlynx, is used to treat a specific type of breast cancer. The company's financial success depends entirely on sales of this drug and expanding its indications.
Profit of companies in the market segment - Breast cancer
Puma Biotechnology is focused on breast cancer treatments. The company's success depends on sales of its only approved drug and the results of new studies. This chart for the biotech sector highlights the high risk of focusing on a single product, where its commercial success or failure directly determines the financial future of the entire company.
Overall market profit
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. Its primary revenue is generated by a single drug. The company's success depends on its sales volume, competition, and new research results, rather than general economic cycles. It's a story driven by specific factors in oncology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Puma Biotechnology
Puma Biotechnology specializes in cancer treatments, with its flagship product, Nerlynx, for breast cancer. This chart shows revenue expectations, which are entirely dependent on sales volumes for this drug. Competition and indication expansion are key factors in forecasting these projections.
%20profit%20of%20the%20company%20Puma%20Biotechnology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Puma-Biotechnology&v=1772513459783 "Graph of future (projected) profit of the company Puma Biotechnology")
Future (predicted) profit of companies in the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its flagship product is Nerlynx, a breast cancer treatment. This chart shows the revenue forecast for the entire breast cancer treatment sector. It reflects expected demand for new treatments. This context is important for assessing the market potential and future sales of Nerlynx.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772513459788 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
Puma Biotechnology specializes in breast cancer treatments. Its success depends on sales of its only approved drug and the results of new trials. Economic cycles, as reflected here, affect it indirectly through healthcare system budgets and patient solvency.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513459791 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its flagship product is Nerlynx, used to treat breast cancer. This chart shows how investors view the current and future sales of this drug, as well as the potential of the company's other developments.
P/S market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its lead product is Nerlynx (neratinib), which is used to treat breast cancer. This chart shows the average valuation in the sector, helping to understand how the market views the commercial success and potential of Nerlynx.
P/S of the market as a whole
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its flagship product is a breast cancer treatment. This market valuation chart helps understand how investors view the company, whose revenue depends on the successful sales of one key drug.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. Future revenues are dependent on sales of its sole commercial product. This chart shows how investors assess its market potential and prospects for expanding its indications.
%20P%2FS%20Puma%20Biotechnology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Puma-Biotechnology&v=1772513459797 "The graph of the company's future (projected) P/S Puma Biotechnology")
Future (projected) P/S of the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on developing cancer treatments. This chart compares market expectations for its future revenue with those of other companies working in the breast cancer field. The estimate reflects investor sentiment about the sales of its key drug, Nerlynx.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772513459798 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
Puma Biotechnology is focused on a breast cancer treatment. The company's success depends almost entirely on sales of this single product. General market optimism, reflected in this chart, influences healthcare system funding, ensuring reimbursement for expensive oncology drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513459801 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. Its revenue is generated by sales of its only approved drug, Nerlynx. This chart shows the commercial success of this drug and its acceptance by the oncology community for the treatment of a specific type of breast cancer.
Sales of companies in the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its sole commercial product, Nerlynx, is designed to treat a specific type of breast cancer. All of the company's revenue is generated from sales of this drug. This graph illustrates the competitive oncology drug market, where success depends on the effectiveness and positioning of a single product.
Overall market sales
Puma Biotechnology focuses on breast cancer treatments. Its commercial success depends on sales of its single approved drug. This business isn't directly tied to economic cycles, but the overall economic situation, reflected here, impacts healthcare budgets and the availability of expensive cancer drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on cancer treatment. Its flagship product is Nerlynx, a drug for the treatment of a specific type of breast cancer. This chart shows analysts' expectations for Nerlynx sales and its potential for use in other cancer types.
%20sales%20of%20the%20company%20Puma%20Biotechnology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Puma-Biotechnology&v=1772513459813 "Schedule of future (projected) sales of the company Puma Biotechnology")
Future (projected) sales of companies in the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company focused on developing cancer treatments, with its lead product targeting breast cancer. The data in this chart shows the outlook for the oncology sector, allowing one to assess how sales of the key drug and its expansion efforts impact the company's future.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772513459815 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
Puma Biotechnology specializes in breast cancer treatments. This graph, reflecting healthcare costs, is important to the company. Stable funding for oncology programs and the willingness of insurance systems to cover expensive treatments are key factors for the commercial success of Puma's drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513459816 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer, particularly breast cancer. Its lead product is already on the market. This chart shows how the company is converting sales of its targeted oncology drug into profit by reinvesting in further research.
Market segment marginality - Breast cancer
Puma Biotechnology specializes in breast cancer treatments. Their flagship product is Nerlynx. Focusing on a single disease allows the company to gain in-depth market insight. This chart shows how successfully the company is commercializing its drug and managing costs while competing with major pharmaceutical giants in the oncology field.
Market marginality as a whole
Puma Biotechnology is a biopharmaceutical company focused on a single commercial drug for the treatment of breast cancer. Unlike the overall picture of profitability, their story is one of an attempt to maximize sales of this product and find new applications for it. Their profitability depends entirely on the success of this single drug.
Employees in the company, segment and market as a whole
Number of employees in the company Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer treatments. This graph shows the team working to advance their approved breast cancer drug. The size of the team reflects its commercial and R&D efforts.
Share of the company's employees Puma Biotechnology within the market segment - Breast cancer
Puma Biotechnology specializes in developing cancer treatments, with its flagship product being a breast cancer treatment. This chart shows its market share in a narrow oncology niche. It reflects the company's focus and the team's dedication to providing patients with new treatment options and improving their prognosis.
Number of employees in the market segment - Breast cancer
Puma Biotechnology specializes in breast cancer treatments. This chart shows employment in the oncology research sector. The staffing dynamics, especially following the approval of its key drug, reflect efforts to commercialize it and conduct further research to expand its indications.
Number of employees in the market as a whole
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatment. Its only commercial product, Nerlynx, is used to prevent recurrence. This graph, which reflects overall employment, highlights the depth and complexity of modern pharmaceuticals, which require significant investment and highly skilled professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Puma Biotechnology (PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company focused on cancer treatment. Its main product is Nerlynx. This chart shows a very high market capitalization per employee. The company's value is determined by the patent for this drug and its sales potential. A small team can manage a product worth hundreds of millions of dollars.
%20of%20the%20company%20Puma%20Biotechnology%20(PBYI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Puma-Biotechnology-PBYI&v=1772513459839 "Chart of market capitalization per employee (in thousands of dollars) of the company Puma Biotechnology (PBYI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
Puma Biotechnology specializes in breast cancer treatments. Its flagship product is Nerlynx. For a biopharmaceutical company with a single key drug, this metric reflects how the market perceives its current and future sales. The chart provides insight into how effectively the company's commercial team is monetizing this drug.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772513459841 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Puma Biotechnology is a biopharmaceutical company whose main product is Nerlynx, a treatment for a certain type of breast cancer. Its value depends almost entirely on the success of this drug. This chart shows how the market values the small team's ability to maximize sales and expand the use of its key asset.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513459844 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Puma Biotechnology (PBYI)
Puma Biotechnology (PBYI) is a biopharmaceutical company whose primary product is Nerlynx, a treatment for breast cancer. This chart shows how successfully the company is commercializing this single asset. It measures how much revenue their focused sales and R&D team is generating.
%20Chart%20Puma%20Biotechnology%20(PBYI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Puma-Biotechnology-PBYI&v=1772513459846 "Company Profit Per Employee (in thousands of dollars) Chart Puma Biotechnology (PBYI)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company whose primary product is Nerlynx, a treatment for HER2-positive breast cancer. Their business is commercializing a niche oncology drug. This chart shows the benchmark for employee profitability in the pharmaceutical industry. It's important for assessing how effectively the Puma team is monetizing their product.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772513459849 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Puma Biotechnology (PBYI) is a biotech company whose primary (and virtually only) commercial product is Nerlynx, a breast cancer treatment. It's a risky model. This chart shows how effectively their small commercial team can maximize sales of this single, highly niche and expensive drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513459851 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Puma Biotechnology (PBYI)
Puma Biotechnology is a biopharmaceutical company focused on breast cancer treatments. This graph shows the life cycle of its core product. Revenue per employee is directly related to sales of its single approved drug and the team's efforts to expand its use and enter new markets.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Puma-Biotechnology-PBYI&v=1772513459863 "Sales chart per company employee Puma Biotechnology (PBYI)")
Sales per employee in the market segment - Breast cancer
Puma Biotechnology (PBYI) is a biopharmaceutical company focused on oncology. Their main product is Nerlynx, a treatment for HER2-positive breast cancer. This chart shows how much revenue each employee (including the sales team) generates from sales of this drug. This is an indicator of their commercial performance.
Sales per employee for the market as a whole
Puma Biotechnology (PBYI) is a biotech company whose only approved product (Nerlynx) is used to treat a specific type of breast cancer. It's a niche oncology drug. This chart shows how successfully their focused commercial team generates revenue from sales of this single, yet important drug, while operating in the competitive oncology market.
Short shares by company, segment and market as a whole
Shares shorted by company Puma Biotechnology (PBYI)
Puma Biotechnology is a biopharmaceutical company whose main product is Nerlynx, a breast cancer treatment. This chart shows bearish bets. The shorts may be due to Nerlynx sales not meeting expectations due to its side effects (diarrhea) and the highly competitive market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Puma-Biotechnology-PBYI&v=1772513459876 "Short Shares Chart for the Company Puma Biotechnology (PBYI)")
Shares shorted by market segment - Breast cancer
Puma Biotechnology (PBYI) is a biopharmaceutical company focused on a single product (Nerlynx) for the treatment of breast cancer. This chart shows the betting against the specialty pharmaceutical sector. The rising betting against the industry may reflect investor concerns about the drug's severe side effects, which limit its sales and market potential.
Shares shorted by the overall market
Puma Biotechnology essentially has one commercial product for the treatment of breast cancer. The company's success depends on its sales and expanding indications. While cancer treatment is not a discretionary expense, high levels of market fear (as shown in this chart) can still negatively impact sentiment around biotechs with a high product concentration.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Puma Biotechnology (PBYI)
Puma Biotechnology focuses on breast cancer treatments. Success depends on its key drug, Nerlynx. A chart above 70 may reflect strong Nerlynx sales or positive R&D news. A level below 30 is often associated with concerns about competition or slowing sales growth.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Puma-Biotechnology-PBYI&v=1772513459890 "RSI 14 indicator chart for the company's stock Puma Biotechnology (PBYI)")
RSI 14 Market Segment - Breast cancer
Puma Biotechnology is a biopharmaceutical company whose lead product (NERLYNX) is used to treat HER2-positive breast cancer. The company's success depends on sales of this drug. This chart shows the overall sentiment in the breast cancer biotech sector. It helps separate the PBYI trend from the general "noise" in the biotech sector.
RSI 14 for the overall market
Puma Biotechnology (PBYI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PBYI (Puma Biotechnology)
Puma Biotechnology is a biopharmaceutical company whose primary (and only) product is Nerlynx, a treatment for HER2-positive breast cancer. This chart shows the average price target from analysts, which is entirely dependent on their sales volume and indication expansion forecasts for Nerlynx.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PBYI-Puma-Biotechnology&v=1772513459898 "A chart showing analyst consensus forecasts for the expected stock price. PBYI (Puma Biotechnology)")
The difference between the consensus estimate and the actual stock price PBYI (Puma Biotechnology)
Puma Biotech (PBYI) is a single-product biotech company. Its key asset is Nerlynx, an approved drug for the treatment of a specific type of breast cancer (HER2+). This chart shows the difference between the consensus estimate and the price. It reflects analysts' belief in Nerlynx's continued sales growth and broader use.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PBYI-Puma-Biotechnology&v=1772513459908 "A chart showing the difference between the consensus forecast and the actual stock price. PBYI (Puma Biotechnology)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
Puma Biotechnology (PBYI) is an oncology company focused on breast cancer. Its only drug (Nerlynx) is used to prevent recurrence in HER2+ patients *after* primary therapy. This chart shows analysts' overall expectations for the breast cancer treatment sector. It reflects whether experts believe there will be demand for "extended" therapy.
Analysts' consensus forecast for the overall market share price
Puma Bio is a "biotech" of "one" "product" (Nerlynx, "breast" cancer). This chart of overall market sentiment is important. "Demand" for "oncology" is "protected." In a "recession" (pessimism), "investors" "appreciate" the "non-cyclical" nature of PBYI's "business." Market "optimism" "can" "help" "finance" R&D for "new" "indications" for the "drug."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Puma Biotechnology
Puma Biotechnology (PBYI) is a single-product company. Their business is Nerlynx, a drug for the treatment of a specific type of breast cancer (HER2+). This chart is an indicator of their battle. It measures their ability (despite side effects) to maintain share in this competitive market and their efforts to expand Nerlynx to other cancer types.
AKIMA Market Segment Index - Breast cancer
Puma Biotechnology is a biopharmaceutical company whose main product (Nerlynx) is used to treat a specific type of breast cancer. This chart shows the average index for the sector (breast cancer). It allows investors to assess how Puma, with its highly specialized product, compares to the oncology industry average.
The AKIM Index for the overall market
Puma Biotechnology is a biopharmaceutical company commercializing the breast cancer drug Nerlynx. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this mature biotech company, dependent on sales of a single product, compares to overall economic trends in healthcare.
